Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer

Bruno R, Hille D, Riva A, et al. J Clin Oncol. 1998;16:187-96

This study demonstrated that it was possible to evaluate docetaxel pharmacokinetics in a large phase II clinical trial to investigate pharmacodynamic relationships.  Correlation of docetaxel exposure to both neutropenia and time to progression were found.

http://ascopubs.org/doi/pdf/10.1200/JCO.1998.16.1.187

Start typing and press Enter to search